Open Heart

FEBRUARY 17, 2025

Background Despite limited beneficial evidence, mechanical circulatory support (MCS) is commonly used in patients with acute myocardial infarction-related cardiogenic shock (AMI-CS). In this Dutch registry, we investigated MCS usage, associated patient characteristics and clinical outcomes.

Cardiogenic Shock 52

Cardiogenic Shock Myocardial Infarction Aortic Outcomes 52

Frontiers in Cardiovascular Medicine

JANUARY 28, 2025

Long COVID-19 was associated with a higher risk of thromboembolic disorders [HR 3.12 (1.60, 6.08)], coronary heart disease [HR 1.61 (1.13, 2.31)], stroke [HR 1.71 (1.07,2.72)], arrhythmia [HR 1.60 (1.13, 2.26)], cardiomyopathy [HR 1.71 (1.12, 2.61)], myocarditis [HR 6.11 (4.17,8.94)], hypertension [HR 1.70 (1.56, 1.85)], heart failure [HR 1.72 (1.15,2.59)] (..)

COVID-19 95

COVID-19 Cardiogenic Shock Cardiomyopathy Outcomes 95

American College of Cardiology

FEBRUARY 1, 2024

What are the characteristics and outcomes of cardiogenic shock (CS) in children hospitalized for acute decompensated heart failure (ADHF)?

Cardiogenic Shock 66

Cardiogenic Shock Outcomes Heart Failure Hospital 66

CardiacWire

SEPTEMBER 25, 2024

Windtree Therapeutics’ istaroxime appears to have scored in its latest Phase 2b trial , showing that the steroidal drug significantly improves systolic blood pressure in cardiogenic shock patients. That could be a big deal in the cardiogenic shock space, which many believe is still in need of more effective treatments.

Cardiogenic Shock 59

Cardiogenic Shock Blood Pressure Heart Failure Cardiac Function 59

Circulation

FEBRUARY 26, 2024

Cardiogenic shock continues to portend poor outcomes, conferring short-term mortality rates of 30% to 50% despite recent scientific advances. Age is a nonmodifiable risk factor for mortality in patients with cardiogenic shock and is often considered in the decision-making process for eligibility for various therapies.

Cardiogenic Shock 74

Cardiogenic Shock Best Practices Heart Transplant Transplant 74

DAIC

DECEMBER 18, 2024

with SmartAssist and Impella CP with SmartAssist heart pumps, granting premarket approval (PMA) for use in specific pediatric patients with symptomatic acute decompensated heart failure (ADHF) and cardiogenic shock. and Impella CP, both left-sided heart pumps, for pediatric patients with symptomatic ADHF and cardiogenic shock.

Pediatrics 52

Pediatrics Cardiogenic Shock Heart Failure Quality of Life 52

Journal of the American Heart Association

JANUARY 19, 2024

BackgroundVenoarterial extracorporeal membrane oxygenation (VA‐ECMO) is increasingly used for patients with cardiogenic shock. Although Impella or intra‐aortic balloon pump (IABP) is frequently used for left ventricular unloading (LVU) during VA‐ECMO treatment, there are limited data on comparative outcomes. P<0.001).ConclusionsIn

Cardiogenic Shock 65

Cardiogenic Shock Aortic Hospital Outcomes 65

The American Journal of Cardiology

JANUARY 25, 2025

Publication date: Available online 24 January 2025 Source: The American Journal of Cardiology Author(s): Eric J. Hall, Colby R. Ayers, Nicholas S. Hendren, Christopher Clark, Amit Saha, Hadi Beaini, Isabella L. Alexander, Evan P. Gee, Ian R. McConnell, Emily S. Samson, Roslyn J. Saplicki, Christopher S. Grubb, Grant Tucker, Justin L.

Cardiogenic Shock 40

Cardiogenic Shock Hospital Outcomes 40

The American Journal of Cardiology

NOVEMBER 14, 2024

Publication date: Available online 14 November 2024 Source: The American Journal of Cardiology Author(s): Pedro Arturo Villablanca, Raef Ali Fadel, Gennaro Giustino, Ahmad Jabri, Mir Babar Basir, Jennifer Cowger, Khaldoon Alaswad, Brian O'Neill, Pedro Engel Gonzalez, Gillian Grafton Gyzm, Tiberio Frisoli, James Lee, Lindsey Aurora, Sarah Gorgis, Hassan (..)

Cardiogenic Shock 40

Cardiogenic Shock Outcomes 40

Dr. S. Venkatesan MD

DECEMBER 29, 2023

Cardiogenic shock (CS)is the most feared event following STEMI. Outcome There are differing data about prognosis of CS in STEMI vs NSTEMI. Ironically, in many patients of CS in NSTEMI, the outcome can be worse than STEMI, as there is no single culprit and myocardial salvage does not appear to be a primary issue.

Cardiogenic Shock 52

Cardiogenic Shock STEMI Myocardial Infarction Document 52

Frontiers in Cardiovascular Medicine

JANUARY 3, 2024

Patients at each shock stage may behave and present differently with a spectrum of shock severity and adverse outcomes. Shock severity, shock aetiology, and several factors should be integrated in management decision-making.

Cardiogenic Shock 90

Cardiogenic Shock Myocardial Infarction Heart Failure Outcomes 90

Circulation: Heart Failure

MARCH 28, 2025

Cardiogenic shock (CS) remains a significant challenge in cardiovascular medicine, characterized by substantial morbidity and mortality. Historically, patient outcomes in CS have been varied, highly dependent on the timeliness of interventions and the expertise available at treating centers.

Cardiogenic Shock 40

Cardiogenic Shock Article Innovation Heart Failure 40

Circulation

NOVEMBER 11, 2024

Cardiogenic shock rates were highest among SV-CHD patients, with significant fluctuations, followed by DV-CHD patients. Variations in cardiogenic shock, MCS usage, and cardiac transplants emphasize the need for adaptive clinical practices to optimize patient outcomes. Patients without CHD were older (mean age 71.5

Cardiogenic Shock 40

Cardiogenic Shock Congenital Heart Disease Heart Failure Congenital 40

European Journal of Heart Failure

FEBRUARY 5, 2025

Aims Among patients with cardiogenic shock, immediate initiation of extracorporeal membrane oxygenation (ECMO) did not demonstrate any benefit at 30days. The present study evaluated 1-year clinical outcomes of the Extracorporeal Membrane Oxygenation in the therapy of Cardiogenic Shock (ECMO-CS) trial.

Cardiogenic Shock 40

Cardiogenic Shock ICU Outcomes Cardiac Arrest 40

European Journal of Heart Failure

DECEMBER 19, 2024

Ventilatory modalities in cardiogenic shock: insights from the AltShock-2 registry. Aims To describe the use and the relation to outcome of different ventilation strategies in a contemporary, large, prospective registry of cardiogenic shock patients.

Cardiogenic Shock 40

Cardiogenic Shock Cardiac Arrest Outcomes Research 40

Journal of the American Heart Association

FEBRUARY 16, 2024

BackgroundClinical outcome of ischemic cardiogenic shock (CS) requiring extracorporeal membrane oxygenation is highly variable, necessitating appropriate assessment of prognosis. Journal of the American Heart Association, Ahead of Print. Fifteen parameters were selected to assess in‐hospital mortality.

Cardiogenic Shock 45

Cardiogenic Shock Hospital Myocardial Infarction Kidney Disease 45

HeartRhythm

APRIL 30, 2024

Atrial fibrillation (AF) is a common sequela in cardiogenic shock (CS) and portends a worse prognosis. Despite its potential to worsen shock, no large-scale studies have investigated the impact of CV on patient outcomes. Electrical cardioversion (CV) is often employed for sinus rhythm restoration.

Cardiogenic Shock 40

Cardiogenic Shock Atrial Fibrillation Outcomes 40

Frontiers in Cardiovascular Medicine

JANUARY 2, 2024

Background Data are lacking on the effects of the alternation of P2Y12 receptor antagonists (P2Y12) on bleeding and outcome in patients with myocardial infarction (MI) with cardiogenic shock (CS). We compared the effects of different P2Y12 and alternation of P2Y12 (combination) on bleeding and outcome in patients with MI and CS.

Cardiogenic Shock 59

Cardiogenic Shock Myocardial Infarction Outcomes 59

Journal of the American Heart Association

MARCH 8, 2024

Cardiogenic shock continues to carry a high mortality rate despite contemporary care, with no breakthrough therapies shown to improve survival over the past few decades. A slowly maturing evidence base has suggested that cardiogenic shock teams may improve patient outcomes.

Cardiogenic Shock 40

Cardiogenic Shock Best Practices Outcomes Education 40

HeartRhythm

APRIL 30, 2024

Electrical storm (ES) complicated by cardiogenic shock (CS) is associated with high risk of morbidity and mortality.

Cardiogenic Shock 40

Cardiogenic Shock Ablation Outcomes 40

Journal of the American Heart Association

FEBRUARY 26, 2025

BackgroundCardiogenic shock carries high mortality. male, 67% acute myocardial infarction, 33% acute decompensated heart failure), 45 (41.3%), 33 (30.3%), and 31 (28.4%) were in SCAI Shock Stages C, D, and E, respectively.

Cardiogenic Shock 40

Cardiogenic Shock Best Practices Myocardial Infarction Pulmonary 40

Journal of the American Heart Association

JANUARY 19, 2024

BackgroundVenoarterial extracorporeal membrane oxygenation (ECMO) provides full hemodynamic support for patients with cardiogenic shock, but optimal timing of ECMO initiation remains uncertain. 1.10];P<0.001).

Cardiogenic Shock 40

Cardiogenic Shock Outcomes Cardiac Arrest Hospital 40

European Journal of Heart Failure

DECEMBER 13, 2023

Impella and venoarterial extracorporeal membrane oxygenation (VA-ECMO) in patients with acute myocardial infarction-related cardiogenic shock (AMICS). Conclusion This is the largest, most recent European cohort study describing outcomes, adverse events, and resource demands based on claims data in patients with Impella and/or VA-ECMO.

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Cardiac Arrest Hospital 40

Circulation: Cardiovascular Interventions

JANUARY 31, 2024

BACKGROUND:In patients with ST-segment–elevation myocardial infarction complicated by cardiogenic shock, primary percutaneous coronary intervention (pPCI) is the preferred revascularization option. The incidence of the primary safety outcome was 10.1% pharmacoinvasive and 46.2% pharmacoinvasive and 46.2% 1.09];P=0.08).CONCLUSIONS:In

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Cardiac Arrest Cardiovascular Interventions 40

Open Heart

DECEMBER 7, 2023

Introduction Cardiogenic shock (CS) complicates 5%–15% of cases of acute myocardial infarction (AMI) with inpatient mortality greater than 40%. The implementation of standardised protocols may improve clinical outcomes in patients with AMI-CS.

Cardiogenic Shock 52

Cardiogenic Shock Myocardial Infarction STEMI Heart Attack 52

Journal of the American Heart Association

JANUARY 31, 2024

BackgroundThe Society for Cardiovascular Angiography and Interventions proposed a staging system (A–E) to predict prognosis in cardiogenic shock. Patients enrolled in the RECOVER III study were assigned a baseline Society for Cardiovascular Angiography and Interventions shock stage. P<0.001).ConclusionsIn

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Outcomes 40

Journal of the American Heart Association

JANUARY 10, 2025

Using inverse probability treatment weighting, we assessed for the association between device type and clinical outcomes. The primary outcome was allcause mortality. The primary outcome was allcause mortality. We identified 2879 patients without CS who underwent PCI with either an intraaortic balloon pump or microaxial LVAD.

Cardiogenic Shock 40

Cardiogenic Shock Outcomes Strokes Stroke 40

Journal of the American Heart Association

DECEMBER 1, 2023

The quarterly prevalence and outcomes were reported. ConclusionsOur study revealed substantial changes in the use of different mechanical circulatory support modalities in acute coronary syndrome complicated with cardiogenic shock, but they did not significantly improve the outcomes. in the first quarter of 2019 to 58.3%

Cardiogenic Shock 40

Cardiogenic Shock Outcomes Aortic Hospital 40

European Journal of Heart Failure

NOVEMBER 23, 2023

Clinical presentation, shock severity and mortality in patients with de novo versus acute-on-chronic heart failure-related cardiogenic shock. ACHF-CS, acute-on-chronic failure-related cardiogenic shock; CI, confidence interval; DNHF-CS, de novo heart failure-related cardiogenic shock; HR, hazard ratio.

Cardiogenic Shock 40

Cardiogenic Shock Heart Failure Blood Pressure Outcomes 40

European Journal of Heart Failure

DECEMBER 12, 2023

Abstract Objectives This study aimed to assess the impact of anemia and iron deficiency (ID) on clinical outcome in patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI). Nevertheless, data concerning the impact of anemia and ID on clinical outcome in patients with CS are scarce.

Cardiogenic Shock 40

Cardiogenic Shock Myocardial Infarction Outcomes Catheterization Laboratory 40

Journal of the American Heart Association

FEBRUARY 14, 2025

BackgroundMultidisciplinary teams and regionalized care systems have been suggested to improve cardiogenic shock (CS) outcomes. Journal of the American Heart Association, Ahead of Print. Methods and ResultsConsecutive patients with CS were evaluated (N=1162).

Cardiogenic Shock 40

Cardiogenic Shock Heart Failure Cardiac Arrest Outcomes 40

European Journal of Heart Failure

DECEMBER 11, 2024

In acute heart failure caused by VHD, symptoms result from rapid haemodynamic changes and subsequent decline in cardiac function, and if left untreated, leads to acute decompensation and cardiogenic shock. After screening a total of 2234 articles, 76 published between 1994 and 2023 were included in subsequent analysis.

Cardiogenic Shock 68

Cardiogenic Shock Heart Disease Heart Failure Bicuspid/Mitral 68

Dr. Smith's ECG Blog

AUGUST 28, 2020

Now appears to be in cardiogenic shock." However, cardiogenic shock usually takes some time to develop, so it is probably subacute." Cardiogenic shock and ACS is an indication for the cath lab, even if you don't think there is OMI. I was texted these ECGs. Then SOB and nausea the next day.

Cardiogenic Shock 40

Cardiogenic Shock Chest Pain Ischemia Stenosis 40

Frontiers in Cardiovascular Medicine

MARCH 27, 2024

Additionally, acute heart failure (AHF) can occur in up to 40% of cases, and its presence can impact the clinical outcomes of patients with IE. Cardiogenic shock (CGS) is often more likely to occur after AHF has taken place. If bacteria invade the blood, infectious shock can occur.

Cardiogenic Shock 64

Cardiogenic Shock Embolism Heart Failure Thrombosis 64

Open Heart

JUNE 5, 2024

We aimed to investigate the prevalence and outcomes of patients with SMuRF-less ACS undergoing percutaneous coronary intervention (PCI) compared with those with SMuRFs. The primary outcome was 30-day mortality. Secondary outcomes included in-hospital and 30-day events. Patients with coronary artery disease were excluded.

Cardiogenic Shock 52

Cardiogenic Shock Myocardial Infarction Outcomes Coronary Artery Disease 52

DAIC

JULY 29, 2024

Magenta's technology stands at the forefront of innovation in the MCS field and has the potential to significantly improve outcomes in patients with severe cardiovascular conditions,” said Eric Snyder, Partner, Venture Investments, Novo Holdings US. “We The financing will be used to advance the company’s U.S. Magenta completed a U.S.

Cardiogenic Shock 105

Cardiogenic Shock Blood Pressure Technology Aortic valve 105

Frontiers in Cardiovascular Medicine

MARCH 10, 2024

There are conflicting sources regarding the relationship between hyperglycemia and outcomes in STEMI patients. We aimed to compile evidence to assess the association between hyperglycemia and adverse outcomes. Mortality was the most often outcome reported related to hyperglycemia. 3.45) and 4.47 (95% CI: 2.54–7.87),

Myocardial Infarction 59

Myocardial Infarction Cardiogenic Shock Article STEMI 59